In short, IVF as a technology is not eugenic, though certain applications, especially embryo screening for traits, can drift toward practices that critics call eugenic. The fault line sits in who decides, what gets selected, and whose lives get devalued along the way, not in the lab work itself.
This article explores where IVF sits in relation to eugenics by examining how each is defined, where selection actually occurs in the lab, and how critics and defenders draw their lines.
Defining Eugenics Before Anything Else
The word “eugenics” was coined by Francis Galton in 1883, but the program it named hardened into something far more coercive than a theory. In 1927, the U.S. Supreme Court ruled in Buck v. Bell that compulsory sterilization of people deemed “unfit” was constitutional, opening a decade of state laws that targeted poor, disabled, and immigrant communities.
Across the Atlantic, Nazi Germany’s T4 Program murdered tens of thousands of disabled children and adults before the broader horrors of the Holocaust. These are the reference points most ethicists reach for when they talk about eugenics, and they explain why the word still carries weight for you.
The Two Modern Senses People Conflate
Contemporary bioethics distinguishes between classical eugenics, which used state power to control who could reproduce, and liberal eugenics, a term popularized by philosopher Nicholas Agar to describe voluntary, market-driven choices that aim at similar outcomes without coercion. The first is a crime against individuals. The second looks more like consumer choice, which is precisely why critics say it deserves the same name.
Most ethicists flag a practice as eugenic when three features line up:
- Coercion or strong pressure on someone’s reproductive life.
- A directed outcome: a specific group of traits or people is steered toward or away from.
- Devaluation of those who carry the “wrong” traits, including people already living with those conditions.
The definition itself is contested, and that ambiguity is exactly what fuels the IVF debate. One person sees a couple screening embryos for a deadly disease and calls it responsible medicine. Another sees the same act and hears a message that disabled lives aren’t worth preventing.
What IVF Actually Does and Where Selection Happens
IVF was developed in the late 1970s as a treatment for infertility. Eggs are retrieved, fertilized with sperm in a lab, and the resulting embryos are transferred into a uterus. The original purpose had nothing to do with genetics; it solved a plumbing problem, whether blocked fallopian tubes, low sperm count, or unexplained failure to conceive.
The ethical question shifted when techniques emerged to examine the embryos themselves before transfer. That’s the moment IVF stopped being only about whether a pregnancy could happen and started being about which pregnancy should happen.
The Three Standard Genetic Screens
Preimplantation genetic testing (PGT) has become routine in many clinics, and it splits into three distinct categories that often get lumped together.
| Test | What It Screens For | Typical Use |
|---|---|---|
| PGT-A (aneuploidy) | Extra or missing chromosomes | Improving implantation rates, reducing miscarriage |
| PGT-M (monogenic) | Single-gene conditions like cystic fibrosis, Huntington’s, sickle cell | Parents who carry a known heritable disease |
| PGT-SR (structural) | Chromosomal rearrangements | Parents with balanced translocations that cause recurrent miscarriage |
These are medical tools, and the conditions they target are usually severe. Avoiding a single-gene disease that kills in childhood is a long way from choosing eye color.
Polygenic Screening and the Trait-Selection Frontier
Since around 2018, commercial labs have offered polygenic embryo screening, which uses statistical models to rank embryos on predicted traits like height, cognitive range, or disease risk across hundreds of variants at once. The science is contested, and predictions are probabilistic at best, but the technology exists. Critics call this the gateway to designer babies. Defenders call it an extension of the same logic that screens for serious disease.
Heritable genome editing, the CRISPR-based changes that would pass into future generations, sits further down the road. After the He Jiankui scandal in 2018, when a Chinese scientist announced edited twins, most jurisdictions reinforced prohibitions, and the World Health Organization has since pushed for a global registry of such research. That door is essentially closed for clinical use today.
How the Two Concepts Overlap and Where They Diverge
Once the definitions are in place, the comparison gets sharper. Classical eugenics involved state power, compulsory sterilization, and murder. Modern IVF involves private decisions, signed consent forms, and clinic billing. The voluntariness gap is enormous, and any honest comparison has to start there.
The Three Practical Categories
Sorting IVF uses into tiers helps keep the conversation honest. Most ethicists and clinics implicitly work with a version of the following split:
- IVF-as-treatment: Used to overcome infertility, no genetic selection involved. Almost no one calls this eugenic.
- IVF-with-medical-PGT: Used to avoid a serious single-gene disease in a known carrier couple. This is the most contested middle ground.
- IVF-with-trait-screening: Used to select for or against non-medical traits like sex, height, or cognitive range. Most critics, including many who accept medical PGT, call this eugenic in form.
That taxonomy doesn’t resolve the ethics, but it stops you from arguing past the person across the table. The defender of medical PGT and the critic of polygenic screening are often closer than the headlines suggest.
The Expressivist Objection, Without the Straw Man
Disability scholars, including Adrienne Asch and Marsha Saxton, have raised an objection that needs careful handling. The argument is not that parents are evil for avoiding a fatal condition. It’s that selecting against a chromosome, a gene, or a trait sends a message to you and to people already living with that trait: your life was the one being screened out.
Phrased bluntly, it sounds like an attack on choice. Phrased precisely, it asks whether the choice can be exercised in a way that doesn’t communicate contempt. Most thoughtful defenders of PGT acknowledge the message matters; they just don’t think it overrides the medical reality. That shared ground is where serious discussion actually happens.
Indirect Pressure Without Explicit Coercion
Critics also point to softer forms of pressure that shape your choices. When insurance only covers IVF with PGT, when clinics market comprehensive packages as the “smart” choice, when employers or extended families quietly expect “the best” outcome, individual preference can aggregate into something that looks eugenic even without a single order being given. The market can do what the state used to do, just with better lighting.
The hardest eugenic questions today aren’t about who’s ordering whom to do what. They’re about the systems that make one choice feel obvious and another feel reckless.
The Strongest Arguments From Critics and Defenders
Both sides have articulated positions sharper than their caricatures. Disability scholarship frames embryo selection as a civil rights issue: a modern extension of the pattern where non-disabled people decide what kinds of lives are worth bringing into being. From that angle, even voluntary screening can reinforce a hierarchy of human value.
The defender’s cornerstone is reproductive autonomy. The American Society for Reproductive Medicine (ASRM) frames PGT as an exercise of the same right that lets a pregnant person decline a test or terminate a pregnancy. From that angle, choosing a healthy child is no more eugenic than choosing a healthy meal.
Where Medical Societies Draw the Lines
ASRM and the American College of Obstetricians and Gynecologists (ACOG) tend to support PGT for serious single-gene conditions and to caution against sex selection for non-medical reasons. Neither endorses polygenic trait screening as standard practice, and both emphasize informed consent. Their position amounts to a medical version of the three-tier split: therapy is fine, enhancement is not, and the boundary is drawn at whether a child faces serious harm without intervention.
Where Both Sides Concede Ground
Critics concede that avoiding a fatal childhood disease through PGT is morally different from screening for height. Defenders concede that clinics can market screening in ways that pressure patients and that polygenic screening carries real risks of misuse. Coercion, commodification, and unequal access are the shared concerns. The disagreement is about how much weight each concern carries relative to individual choice.
Regulation, Markets, and the Politics of Choice
Regulatory frameworks reveal what societies already think, and what they think shapes what you can access. The United Kingdom’s Human Fertilisation and Embryology Authority (HFEA) licenses each embryo-screening test individually and keeps a public registry of approved uses. The United States has no equivalent federal authority; clinics operate under professional guidelines and state-level variation, and polygenic screening has spread through direct-to-clinic offerings faster than any framework has caught up.
With roughly 8 million IVF births worldwide since 1978, this is no longer a fringe ethical question. It is a mainstream medical practice layered with optional technology that has outrun the rules designed for it.
Market Dynamics That Mimic Coercion
When wealthier patients can afford comprehensive PGT and public insurance rarely covers it, the technology sorts itself by class. When employers or countries compete for “the best” talent, embryo screening starts to look like national infrastructure. None of this requires a state order; the incentive structure does the work. The Nuffield Council on Bioethics flagged exactly this dynamic in its 2018 report on genome editing and has raised parallel concerns about reproductive screening more broadly.
| Region | Regulator | PGT for Medical Use | Polygenic Screening |
|---|---|---|---|
| United Kingdom | HFEA (statutory) | Licensed case-by-case | Restricted |
| United States | No federal authority | Widely available | Available, lightly regulated |
| European Union (varies) | National authorities | Generally permitted for serious conditions | Mostly restricted |
The contrast matters because the same technology reads as routine in one country and as ethically fraught in another. Your next question isn’t just what IVF can do; it’s what societies decide it should do.
Where the Rules Stop
Most frameworks have clear rules against heritable genome editing and loose, inconsistent rules around polygenic screening. The frontier is right where the trait-selection question lives, and the gap between law and clinic reality is the space where this entire debate keeps happening.
A Framework for Forming Your Own Position
Three questions cut through the noise better than any slogan. Ask who decides, what is selected, and who is devalued. A private decision by informed adults about avoiding a lethal single-gene disease scores very differently on all three than a market-driven package that ranks embryos on cognitive proxies and is sold to anxious parents.
IVF the technology is not eugenic. Certain applications carry eugenic weight, especially when selection targets traits rather than severe disease, when markets create pressure that mimics coercion, and when the practice communicates that disabled lives are the ones to be screened out. Those three features, voluntariness, target, and message, are where your verdict actually lives.
Reading Slippery-Slope Arguments Carefully
Critics warn that medical PGT leads inevitably to designer babies. Defenders warn that any restriction leads to reproductive policing. Both are slippery-slope arguments, and both deserve the same scrutiny: ask what specific mechanism carries the practice from one tier to the next, and whether that mechanism is currently operating. Vague fears cut both ways, and precise distinctions serve you better than either.
A Closing Posture
The most defensible position is rarely a blanket yes or no. It’s a precise one: IVF-as-treatment is medicine; IVF-with-medical-PGT is contested but defensible under tight conditions; IVF-with-trait-screening carries eugenic risk regardless of who chooses it. Your real work is in keeping those categories separate rather than letting any one case speak for all.
The Verdict
IVF sits at the intersection of medical treatment, consumer choice, and inherited moral language. The technology itself is a tool for overcoming infertility; the controversy arrives when the tool is extended to choosing among embryos, especially by trait. Keep voluntariness, target, and message in view, and the question stops being a slogan fight and starts being an honest ethical calculation for you.
FAQ
Is IVF considered eugenics?
Most ethicists, medical societies, and legal frameworks classify IVF as a fertility treatment rather than eugenics. The label arises when IVF is combined with embryo screening directed at traits, especially when screening is coercive, targets non-medical characteristics, or devalues people already living with the condition being avoided.
Does IVF involve genetic selection?
Standard IVF does not. When you add preimplantation genetic testing (PGT-A, PGT-M, or PGT-SR), the embryos can be screened before transfer, which introduces a selection step. The extent of selection ranges from identifying chromosomal abnormalities to avoiding a serious single-gene disease to ranking embryos by predicted traits in polygenic screening.
What is the difference between IVF and eugenics?
IVF is a medical procedure that assists reproduction, with selection only when screening is added and only for the embryos being transferred. Eugenics historically referred to state-coerced programs aimed at changing the genetic makeup of a population, often by controlling who could reproduce. The two share the word “selection,” but classical eugenics used coercion; modern IVF uses consent.
Can you screen embryos for genetic conditions with IVF?
Yes. PGT-M can identify single-gene conditions such as cystic fibrosis, Huntington’s, and Tay-Sachs when both parents are known carriers. PGT-A screens for chromosomal abnormalities that affect implantation and miscarriage risk. PGT-SR addresses structural rearrangements carried by a parent. Each test has its own indications, accuracy limits, and costs.
What are the ethical concerns of IVF genetic screening?
The main concerns are the expressivist message sent to disabled communities, the indirect pressure that markets and insurance create, the unregulated growth of polygenic trait screening, and the long-term social effect of widespread embryo selection on how societies value different kinds of lives. Medical groups generally accept PGT for serious conditions and reject selection for non-medical traits.
Does choosing embryos during IVF count as eugenics?
It depends on what is being chosen and why. Avoiding a fatal childhood disease in a known carrier situation is widely treated as responsible medicine, not eugenics. Selecting for sex, height, or cognitive proxies tends to draw the eugenics label from both ethicists and disability scholars, especially when the practice is marketed or incentivized rather than freely chosen.
